Chemomab Therapeutics (CMMB) Retained Earnings (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Retained Earnings came in at $124.0 million in Q4 2025, up 6.71% YoY from $116.2 million in Q4 2024, and up 212.95% on a QoQ basis from -$109.7 million in Q3 2025.
Chemomab Therapeutics (CMMB) Retained Earnings (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Retained Earnings data on file, last reported at $124.0 million in Q4 2025.
- Quarterly Retained Earnings rose 6.71% year-over-year to $124.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $124.0 million (up 6.71% YoY) and the FY2025 annual result came in at $124.0 million, up 6.71% from the prior year.
- Retained Earnings advanced to $124.0 million in Q4 2025, from -$109.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $124.0 million in Q4 2025 to a low of -$109.7 million in Q3 2025.
- A 5-year average of $22.0 million and a median of $96.4 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 183.04% — and 2024, when it slumped 190.96%.
- Tracing CMMB's Retained Earnings over 5 years: stood at $97.6 million in 2021, then gained by 3.71% to $101.3 million in 2022, then grew by 4.36% to $105.7 million in 2023, then grew by 9.92% to $116.2 million in 2024, then grew by 6.71% to $124.0 million in 2025.
- The last three Retained Earnings figures came in at $124.0 million (Q4 2025), -$109.7 million (Q3 2025), and -$108.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 123.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 123.95 Mn |
| Sep 30, 2025 | -109.75 Mn |
| Jun 30, 2025 | -108.00 Mn |
| Mar 31, 2025 | -105.95 Mn |
| Dec 31, 2024 | 116.16 Mn |
| Sep 30, 2024 | -99.66 Mn |
| Jun 30, 2024 | -96.18 Mn |
| Mar 31, 2024 | -92.55 Mn |
| Dec 31, 2023 | 105.68 Mn |
| Sep 30, 2023 | -84.62 Mn |
| Jun 30, 2023 | -80.54 Mn |
| Mar 31, 2023 | 101.74 Mn |
| Dec 31, 2022 | 101.26 Mn |
| Sep 30, 2022 | 100.17 Mn |
| Jun 30, 2022 | 99.30 Mn |
| Mar 31, 2022 | 98.51 Mn |
| Dec 31, 2021 | 97.64 Mn |
| Sep 30, 2021 | 96.65 Mn |
| Jun 30, 2021 | 96.21 Mn |
| Mar 31, 2021 | 80.56 Mn |